Comparative Pharmacology
Head-to-head clinical analysis: MENTAX TC versus XOLEGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX TC versus XOLEGEL.
MENTAX-TC vs XOLEGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
Cholestyramine, the active ingredient in XOLEGEL, is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This prevents enterohepatic recirculation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver, thereby lowering serum low-density lipoprotein (LDL) cholesterol.
Apply a thin layer to affected area once daily for 2-4 weeks.
Apply a thin layer to affected areas once daily. Maximum 60 g per week. Do not use on the face, axillae, or groin. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
The terminal elimination half-life is approximately 2.5 hours in adults based on intravenous data, but clinical relevance is minimal due to negligible systemic absorption after topical use.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Following topical application, negligible systemic absorption occurs; any absorbed fraction is primarily eliminated via renal excretion as unchanged drug and metabolites. Biliary/fecal excretion is minimal.
Category C
Category C
Topical Antifungal
Topical Antifungal